ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
Lowey Dannenberg P.C. is investigating ImmunityBio Inc. (NASDAQ: IBRX) for potential violations of federal securities laws. A complaint alleges that the company and an officer misrepresented Anktiva’s capabilities, leading to false and misleading statements about ImmunityBio's business. The firm encourages investors who suffered losses exceeding $50,000 to contact them regarding potential participation in the investigation.
INVESTOR DEADLINE TUESDAY: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD Law
Robbins Geller Rudman & Dowd LLP announced that investors who purchased ImmunityBio, Inc. (IBRX) securities between January 19, 2026, and March 24, 2026, have until May 26, 2026, to seek lead plaintiff status in a class action lawsuit. The lawsuit alleges that ImmunityBio and its Executive Chairman made false and misleading statements regarding their lead product, Anktiva. The stock price reportedly fell 21% after the FDA publicized a warning letter concerning misleading promotional claims for Anktiva.
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
Kahn Swick & Foti, LLC (KSF) has reminded investors of ImmunityBio, Inc. (NASDAQ: IBRX) with significant losses that they have until May 26, 2026, to file lead plaintiff applications in a securities class action lawsuit. This action follows a 21% stock decline after the FDA issued a warning letter regarding misleading claims in an advertisement for the company's cancer therapy, Anktiva. The lawsuit alleges that ImmunityBio and its executives failed to disclose material information and violated federal securities laws during the specified Class Period.
Is ANKTIVA’s BCG Tie-Up And New Patents Altering The Investment Case For ImmunityBio (IBRX)?
ImmunityBio (IBRX) recently announced new data suggesting its ANKTIVA plus BCG treatment for bladder cancer offers stronger responses with fewer side effects, along with FDA acceptance of a Biologics License Application and exclusive rights to the Tokyo-172 BCG strain. These developments, coupled with new patents extending protection through 2035, could significantly enhance ImmunityBio's market position by strengthening its intellectual property and supply chain, despite existing concentration risks on a single asset and ongoing legal challenges. The FDA's upcoming decision on ANKTIVA’s label expansion in January 2027 is a key catalyst for the company's future investment narrative and financial outlook, which analysts project could lead to substantial revenue and earnings growth by 2029.
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the ...
The Schall Law Firm has announced a class action lawsuit against ImmunityBio, Inc. (IBRX) for alleged securities fraud between January 19 and March 24, 2026. Investors who suffered losses due to the company's supposedly false and misleading statements about its Anktiva drug capabilities are encouraged to contact the firm to discuss their rights and participate in the lawsuit before May 26, 2026.
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) for alleged securities fraud. Investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, are encouraged to contact the firm to participate, claiming the company made false and misleading statements regarding its Anktiva drug. The lawsuit alleges that ImmunityBio overstated the drug's capabilities, causing investor damages when the truth was revealed.
IBRX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
Faruqi & Faruqi, LLP is reminding ImmunityBio (IBRX) investors of the May 26, 2026 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that ImmunityBio and its executives made false and misleading statements regarding Anktiva's capabilities and that investors suffered losses as a result. The firm encourages investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, to contact them to discuss their legal options.
ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS
ImmunityBio (IBRX) is facing a securities class action lawsuit after the FDA issued a warning letter concerning misleading efficacy claims made by its executive chairman about its lead product, Anktiva. The FDA stated that claims suggesting Anktiva could treat "all cancers" and ensure long-term cancer-free status for bladder cancer patients were unsubstantiated and misleading. This news caused ImmunityBio shares to plunge over 21%, resulting in a $2 billion market cap loss.
ImmunityBio stock (US45258J1025): FDA accepts ANKTIVA bladder cancer filing and sets 2027 PDUFA date
ImmunityBio's stock surged following news that the FDA accepted a supplemental biologics license application (sBLA) for ANKTIVA in combination with BCG for bladder cancer, setting a PDUFA date for January 6, 2027. This development is significant for the company's transition from a clinical-stage developer to a commercial player, strengthening its position in the bladder cancer treatment market. Investors are closely monitoring ANKTIVA's regulatory progress and commercial evolution as major determinants for future revenue growth and the company's long-term sustainability.
IMMUNITYBIO, INC. INVESTORS WITH LOSSES HAVE UNTIL MAY 26,
Bernstein Liebhard LLP reminds investors of ImmunityBio, Inc. (NASDAQ: IBRX) that they have until May 26, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that the company made false and misleading statements between January 19, 2026, and March 24, 2026, causing investors significant losses. Shareholders who purchased during this period and suffered losses are encouraged to contact the firm for legal options.
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz announced that shareholders of ImmunityBio, Inc. (IBRX) who suffered losses have the opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges that ImmunityBio's CEO, Soon-Shiong, materially overstated the capabilities of Anktiva, making the company's positive statements misleading between January 19, 2026, and March 24, 2026. Investors are encouraged to contact the law firm before the May 26, 2026, lead plaintiff deadline to participate in the ongoing litigation.
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
ImmunityBio announced the FDA's acceptance of its supplemental Biologics License Application (sBLA) for ANKTIVA plus BCG to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary disease. The FDA set a PDUFA target action date of January 6, 2027, with the review focusing on the scientific data supporting the overlap between papillary and carcinoma in situ (CIS) diseases. This potential expansion of ANKTIVA's label aims to provide a much-needed bladder-sparing treatment option for patients who currently have limited choices.
IBRX Stock Jumps Overnight After Major FDA Review Win For Anktiva In Bladder Cancer
ImmunityBio's stock (IBRX) jumped after the FDA accepted its application to expand the use of Anktiva plus BCG for bladder cancer, reversing an earlier refusal. The FDA will review evidence suggesting papillary bladder cancer and carcinoma in situ (CIS) are biologically similar. A final decision is expected by January 6, 2027, potentially broadening Anktiva's application to a larger patient population who no longer respond to standard BCG treatment.
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
The Law Offices of Frank R. Cruz announced a securities fraud class action lawsuit against ImmunityBio, Inc. (IBRX) on behalf of investors who suffered losses. The lawsuit alleges that between January 19, 2026, and March 24, 2026, the company materially overstated the capabilities of its product Anktiva, leading to misleading statements about the company's business and prospects. Investors have until May 26, 2026, to seek to become lead plaintiffs in the lawsuit.
ImmunityBio Secures Five U.S. Patents for Anktiva in Bladder Cancer
ImmunityBio has secured five new U.S. patents for its drug Anktiva in combination with Bacillus Calmette-Guérin (BCG) for treating non-muscle invasive bladder cancer (NMIBC). These patents extend intellectual property protection through 2035, covering various aspects of the therapy including dosing and compositions. The company also announced an exclusive development and supply agreement for a BCG strain, aiming to address persistent BCG shortages and support Anktiva's continued market expansion.
Lost Money on ImmunityBio, Inc. (IBRX)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
The Gross Law Firm has issued a notice to shareholders of ImmunityBio, Inc. (IBRX) encouraging those who purchased shares between January 19, 2026, and March 24, 2026, to join a class action lawsuit. The complaint alleges that the company's statements about Anktiva's capabilities were materially false and misleading. The deadline to seek lead plaintiff appointment is May 26, 2026.
Lost Money on ImmunityBio, Inc. (IBRX)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
The Gross Law Firm is encouraging shareholders of ImmunityBio, Inc. (IBRX) who purchased stock between January 19, 2026, and March 24, 2026, to join a class action lawsuit. The suit alleges that defendants made false and misleading statements about Anktiva's capabilities. Shareholders have until May 26, 2026, to register to be considered for lead plaintiff.
ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026
ImmunityBio, Inc. presented favorable comparative effectiveness data for its therapy nogapendekin alfa inbakicept-pmln (NAI, ANKTIVA®) plus Bacillus Calmette–Guérin (BCG) against nadofaragene firadenovec-vncg and TAR-200 for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) at the AUA 2026 Annual Meeting. NAI+BCG showed higher complete response rates and longer duration of response compared to nadofaragene, and numerically higher 12-month CR rates and fewer treatment-related adverse events compared to TAR-200. These findings reinforce ANKTIVA's role as an immunological backbone for bladder cancer treatments, addressing bladder preservation and response durability concerns for patients.
ImmunityBio Secures Exclusive Tokyo-172 BCG Rights in U.S.
ImmunityBio (IBRX) has secured exclusive 10-year U.S. rights for Tokyo-172 BCG, an intravesical treatment for non-muscle invasive bladder cancer, from Japan BCG Laboratory. This agreement, supported by positive Phase III data, aims to alleviate the chronic
Exclusive Tokyo BCG supply deal expands ImmunityBio (NASDAQ: IBRX) options
ImmunityBio Inc. has signed an exclusive development and supply agreement with Japan BCG Laboratory for the Tokyo-172 strain of BCG for bladder cancer treatment in the U.S. This deal, along with an existing partnership, aims to address chronic BCG shortages. While the Tokyo strain demonstrated non-inferiority to TICE BCG in a Phase III trial, it remains investigational, and ImmunityBio will lead all regulatory and commercialization efforts, with no upfront payments.
ImmunityBio, Inc. Deadline: IBRX Investors with Losses in Excess of $100K Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
The Rosen Law Firm has filed a securities class action lawsuit against ImmunityBio, Inc. (IBRX) on behalf of investors who purchased securities between January 19, 2026, and March 24, 2026. The lawsuit alleges that ImmunityBio's CEO, Patrick Soon-Shiong, overstated the capabilities of Anktiva, leading to false and misleading statements about the company's prospects. Investors with losses exceeding $100,000 can seek to serve as lead plaintiff before the May 26, 2026 deadline.
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) for securities fraud, alleging the company made false and misleading statements about its Anktiva drug. Investors who purchased securities between January 19, 2026, and March 24, 2026, are encouraged to contact the firm to discuss their rights before May 26, 2026. The lawsuit claims that ImmunityBio overstated the capabilities of its drug, leading to investor losses when the truth became known.
What's Going On With ImmunityBio Stock Monday? - ImmunityBio (NASDAQ:IBRX)
ImmunityBio (IBRX) entered an exclusive U.S. development and supply agreement with Japan BCG Laboratory for the Tokyo strain of BCG for bladder cancer treatment. This partnership follows positive Phase 3 data showing the Tokyo strain's non-inferiority to TICE BCG in certain bladder cancer patients and aims to address the ongoing BCG shortage in the U.S. Concurrently, ImmunityBio secured five new U.S. patents for its ANKTIVA plus BCG platform, extending intellectual property protection for its bladder cancer franchise through at least 2035.
ImmunityBio stock gains on five new U.S. patent awards
ImmunityBio Inc. shares increased by 4.5% in premarket trading after the company announced five new U.S. patents for its ANKTIVA plus BCG combination therapy for bladder cancer. These patents protect the treatment of non-muscle invasive bladder cancer and extend through at least 2035, supporting the company's commercial franchise and ongoing clinical trials. The company's CEO, Richard Adcock, highlighted 700% year-over-year revenue growth and expanding clinical utility for the therapy.
ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035
ImmunityBio, Inc. has been issued five comprehensive U.S. patents protecting its ANKTIVA and Bacillus Calmette-Guérin (BCG) combination for cancer treatment, with terms extending through at least 2035. These patents cover the composition of combinations, specific intravesical dosing regimen, the two-vial commercial kit, and methods of treating non-muscle invasive bladder cancer (NMIBC), including BCG-naïve disease. This intellectual property strengthens ImmunityBio's commercial franchise and supports its ongoing clinical trials and supply chain diversification efforts, including an exclusive U.S. supply agreement for the Tokyo-172 BCG strain.
ImmunityBio Signs exclusive US agreement with Japan BCG Laboratory
ImmunityBio, Inc. has announced an exclusive US development and supply agreement with Japan BCG Laboratory (JBL) for the Tokyo strain of BCG (Tokyo-172 BCG). This agreement grants ImmunityBio exclusive rights to develop, import, and commercialize intravesical Tokyo-172 BCG in the US, with plans to seek FDA approval. The Tokyo strain has shown non-inferiority to TICE BCG in treating high-grade non-muscle invasive bladder cancer and has been used in Japan for almost 30 years.
ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035
ImmunityBio has announced comprehensive U.S. patents covering the combination of its IL-15 receptor agonist ANKTIVA (nogapendekin alfa inbakicept-pmln) with Bacillus Calmette-Guérin (BCG) for cancer treatment, with terms extending through at least 2035. These five patents protect the approved ANKTIVA plus BCG product, specific intravesical dosing regimens, two-vial commercial kits, and methods of treating non-muscle invasive bladder cancer (NMIBC), including BCG-naïve disease. This intellectual property position solidifies ImmunityBio's commercial franchise and supports its ongoing efforts to expand ANKTIVA's clinical utility and secure BCG supply.
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) and certain officers, alleging federal securities law violations. The lawsuit claims that ImmunityBio made materially false and misleading statements between January 19, 2026, and March 24, 2026, regarding its business, operations, and prospects, specifically concerning overstatements about Anktiva's capabilities. Investors who purchased ImmunityBio securities during this period are encouraged to join the case, with a lead plaintiff deadline of May 26, 2026.
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
ImmunityBio has signed an exclusive U.S. agreement with Japan BCG Laboratory (JBL) for the Tokyo strain of BCG (Tokyo-172 BCG) to address the persistent BCG shortage in the United States. This partnership provides ImmunityBio with a second potential source of BCG, alongside its existing collaboration with the Serum Institute of India for recombinant BCG. The agreement follows positive Phase III trial results for Tokyo-172 BCG, demonstrating its non-inferior efficacy compared to TICE BCG for high-grade non-muscle invasive bladder cancer.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus
ImmunityBio (IBRX.O) secured exclusive U.S. rights for Japan BCG Laboratory's Tokyo-172 strain for bladder cancer treatment, a move expected to impact its stock trading on Monday. The company's main drug, Anktiva, is already approved for use with BCG, and this new agreement aims to address a decade-long BCG shortage for patients. Despite strong Q1 product revenue, ImmunityBio faces regulatory scrutiny over marketing claims and a need for additional funding, making Monday's market reaction closely watched by investors.
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
ImmunityBio announced an exclusive U.S. agreement with Japan BCG Laboratory for the Tokyo-172 strain of BCG, aiming to address the long-standing BCG shortage in the United States for non-muscle invasive bladder cancer. This agreement, following positive Phase III trial results, positions ImmunityBio to seek FDA approval and become the sole U.S. applicant for this BCG strain. This initiative, alongside an existing partnership with Serum Institute of India for recombinant BCG, is designed to provide U.S. urologists and patients with a more reliable and diversified BCG supply.
Vanguard Group Inc. Has $64.90 Million Stake in ImmunityBio, Inc. $IBRX
Vanguard Group Inc. significantly increased its stake in ImmunityBio, Inc. to $64.90 million, now owning approximately 3.33% of the company despite recent legal and regulatory challenges. ImmunityBio faces a securities class-action lawsuit and FDA scrutiny over Anktiva's promotional claims, leading to stock volatility. However, some analysts maintain a bullish outlook, with HC Wainwright reiterating a Buy rating and a $15 price target, while the consensus on MarketBeat is a "Moderate Buy" with a $14.20 target.
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
ClaimsFiler is alerting investors with losses over $100,000 in ImmunityBio, Inc. (IBRX) to a lead plaintiff deadline of May 26, 2026, in a securities class action lawsuit. The lawsuit alleges that ImmunityBio failed to disclose material information between January 19, 2026, and March 24, 2026, specifically regarding a U.S. Food and Drug Administration warning letter about misrepresentations of its drug Anktiva. The revelation of this warning letter led to a significant 21% drop in ImmunityBio's share price.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX
Pomerantz LLP has announced a class action lawsuit against ImmunityBio, Inc. (IBRX) on behalf of investors who suffered losses. The lawsuit alleges securities fraud and unlawful business practices by ImmunityBio and its officers, specifically regarding misleading promotions of its bladder-cancer drug Anktiva, which led to an FDA warning and a significant stock price drop. Investors with losses during the Class Period have until May 26, 2026, to seek appointment as Lead Plaintiff.
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
Lieff Cabraser Heimann & Bernstein, LLP is encouraging ImmunityBio, Inc. (IBRX) investors who purchased securities between January 19, 2026, and March 24, 2026, to contact them regarding a pending securities class action. The lawsuit alleges that ImmunityBio's Executive Chairman, Patrick Soon-Shiong, made misleading statements about the capabilities of Anktiva, leading to a significant stock price drop after the FDA issued a warning letter. The deadline to apply to be a lead plaintiff is May 26, 2026.
IBRX 12-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens Berman
Hagens Berman has issued a 12-day deadline alert for investors in ImmunityBio (IBRX) following a securities class action lawsuit. The lawsuit stems from an FDA warning letter concerning misleading efficacy claims made by ImmunityBio's executive chairman regarding their lead biologic product, Anktiva, for treating cancers beyond its FDA-approved indication for bladder cancer. This news led to a over 21% drop in ImmunityBio's share price, erasing nearly $2 billion in market capitalization.
IBRX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
Faruqi & Faruqi, LLP is reminding investors of ImmunityBio (IBRX) that the deadline to seek the role of lead plaintiff in a securities class action lawsuit is May 26, 2026. The lawsuit alleges that ImmunityBio and its executives made false and misleading statements regarding Anktiva's capabilities, leading to investor damages. Investors who purchased IBRX securities between January 19, 2026, and March 24, 2026, and experienced losses are encouraged to contact the firm.
IMMUNITYBIO, INC. INVESTORS WITH LOSSES HAVE UNTIL MAY 26,
Bernstein Liebhard LLP reminds ImmunityBio, Inc. (NASDAQ: IBRX) investors that they have until May 26, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that ImmunityBio made false and misleading statements, leading to artificially inflated stock prices and significant losses for investors who purchased shares between January 19, 2026, and March 24, 2026. Investors who suffered losses are encouraged to contact Bernstein Liebhard LLP for legal options.
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of a class action lawsuit against ImmunityBio, Inc. (IBRX) for alleged securities fraud. The lawsuit claims that the company made false and misleading statements about its Anktiva drug, causing investors to suffer damages. Investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, have until May 26, 2026, to contact the firm to participate.
INVESTOR ALERT: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RGRD Law
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against ImmunityBio, Inc. (IBRX) for investors who purchased securities between January 19, 2026, and March 24, 2026. The lawsuit alleges that ImmunityBio and its Executive Chairman made false and misleading statements regarding the capabilities of its lead product, Anktiva. A warning letter from the FDA regarding misbranding and misleading claims about Anktiva's ability to cure cancer led to a significant drop in ImmunityBio's stock price.
Lost Money on ImmunityBio, Inc. (IBRX)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
The Gross Law Firm has issued a notice for ImmunityBio, Inc. (IBRX) shareholders who purchased shares between January 19, 2026, and March 24, 2026. A class action lawsuit alleges that the company's statements about Anktiva's capabilities and its business prospects were materially false or misleading. Shareholders are encouraged to contact the firm by the May 26, 2026 deadline to learn more about joining the suit.
Lost Money on ImmunityBio, Inc. (IBRX)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
The Gross Law Firm has issued a notice for shareholders of ImmunityBio, Inc. (IBRX) who purchased shares between January 19, 2026, and March 24, 2026. This class action lawsuit alleges that ImmunityBio's CEO, Soon-Shion, overstated the capabilities of the company's product, Anktiva. Shareholders are encouraged to contact the law firm to learn about participating in the suit, with a deadline to seek lead plaintiff appointment set for May 26, 2026.
Lost Money on ImmunityBio, Inc. (IBRX)? Join Class Action Suit S
The Gross Law Firm has issued a notice for shareholders of ImmunityBio, Inc. (IBRX) who purchased shares between January 19, 2026, and March 24, 2026. A class action lawsuit alleges that the company's statements about Anktiva's capabilities were materially false and misleading. Affected shareholders are encouraged to contact the firm by the May 26, 2026 deadline to potentially join the suit and seek recovery.
IBRX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
Faruqi & Faruqi, LLP is investigating potential claims against ImmunityBio (IBRX) and reminds investors of the May 26, 2026 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that ImmunityBio and its executives made false and misleading statements about Anktiva's capabilities, specifically that CEO Patrick Soon-Shiong materially overstated them, leading to investor damages. ImmunityBio's stock price fell significantly on January 23, 2026, after the company announced updated Phase 2 clinical results for QUILT 3.078, revealing that the median overall survival, a primary endpoint, had not yet been reached.
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)
Bernstein Liebhard LLP has announced a securities class action lawsuit filed against ImmunityBio, Inc. (IBRX) on behalf of investors who purchased shares between January 19, 2026, and March 24, 2026. The lawsuit alleges ImmunityBio made misrepresentations regarding its lead biologic product, ANKTIVA. Investors who wish to serve as lead plaintiff must file papers by May 26, 2026.
Lost Money on ImmunityBio, Inc. (IBRX)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
The Gross Law Firm has issued a notice for shareholders of ImmunityBio, Inc. (NASDAQ: IBRX) who lost money on their investments. The firm is encouraging shareholders who purchased shares between January 19, 2026, and March 24, 2026, to join a class action lawsuit, alleging that ImmunityBio made materially false or misleading statements regarding Anktiva's capabilities. The deadline to seek lead plaintiff appointment in this case is May 26, 2026.
Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors
The Portnoy Law Firm has announced a class action lawsuit for investors of ImmunityBio, Inc. (IBRX) who purchased securities between January 19, 2026, and March 24, 2026. This action follows a significant drop in ImmunityBio's stock price after an announcement on January 23, 2026, revealed that the primary endpoint of "median overall survival" had not yet been reached in a Phase 2 glioblastoma immunotherapy trial, leading to a loss of investor confidence. Investors have until May 26, 2026, to file a lead plaintiff motion.
IBRX stock can't shake FDA delay overhang: Founder touts Saudi and Greece progress with Anktiva as bright spots
The article from MSN refers to NantHealth (IBRX) stock performance. It notes that the stock is affected by an FDA delay, but its founder is highlighting positive developments for Anktiva in Saudi Arabia and Greece as potential upsides.
IBRX SHAREHOLDER RIGHTS ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026
Faruqi & Faruqi, LLP is investigating potential claims against ImmunityBio, Inc. (NASDAQ: IBRX) and reminds investors that the deadline to seek lead plaintiff in a federal class action lawsuit is May 26, 2026. The lawsuit alleges that ImmunityBio and its executives made false and misleading statements regarding Anktiva's capabilities, particularly after a January 23, 2026 press release revealed that median overall survival for a glioblastoma trial had not yet been reached. Investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, and incurred losses are encouraged to contact the firm to discuss their legal rights.
FinancialContent - ImmunityBio, Inc. (NASDAQ: IBRX) Investors Who Have Suffered Losses - Contact Kaplan Fox before May 26, 2026 Lead Plaintiff Deadline
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of investors who purchased securities between January 19, 2026, and March 24, 2026. The lawsuit stems from a warning letter issued by the FDA to ImmunityBio regarding "false or misleading" advertising of its product Anktiva, which caused the company's stock to fall 21%. Investors who suffered losses are encouraged to contact Kaplan Fox before the lead plaintiff deadline of May 26, 2026.
